Drug‐coated balloon versus uncoated percutaneous transluminal angioplasty for the treatment of atherosclerotic lesions in the superficial femoral and proximal popliteal artery: 2‐year results of the MDT‐2113 SFA Japan randomized trial
Objectives To assess the longer‐term safety and efficacy of the IN.PACT Admiral (MDT‐2113) drug‐coated balloon (DCB) for the treatment of de novo and non‐stented restenotic lesions in the superficial femoral and/or proximal popliteal arteries versus uncoated percutaneous transluminal angioplasty (PT...
Gespeichert in:
| Veröffentlicht in: | Catheterization and cardiovascular interventions 2019-03, Vol.93 (4), p.664-672 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 672 |
|---|---|
| container_issue | 4 |
| container_start_page | 664 |
| container_title | Catheterization and cardiovascular interventions |
| container_volume | 93 |
| creator | Iida, Osamu Soga, Yoshimitsu Urasawa, Kazushi Saito, Shigeru Jaff, Michael R. Wang, Hong Ookubo, Hiroko Yokoi, Hiroyoshi |
| description | Objectives
To assess the longer‐term safety and efficacy of the IN.PACT Admiral (MDT‐2113) drug‐coated balloon (DCB) for the treatment of de novo and non‐stented restenotic lesions in the superficial femoral and/or proximal popliteal arteries versus uncoated percutaneous transluminal angioplasty (PTA) in a Japanese cohort.
Background
Although DCBs are the newest endovascular strategy for patients with peripheral artery disease presenting with femoropopliteal lesions, there remains a paucity of results in non‐Caucasian populations.
Methods
IN.PACT SFA Japan is an independently‐adjudicated, prospective, multicenter, randomized, single‐blinded trial. Endpoints through 2 years included primary patency and a composite safety endpoint of freedom from device‐ and procedure‐related death through 30 days, freedom from target limb major amputation and freedom from clinically‐driven target vessel revascularization at 24 months.
Results
One hundred patients were assigned by 2:1 randomization to treatment with the IN.PACT Admiral DCB (n = 68) or PTA (n = 32). The groups were well‐matched at baseline. Mean lesion length for the DCB and PTA groups were 9.15 ± 5.85 and 8.89 ± 6.01 cm (P = 0.838), respectively. Patients treated with DCB exhibited superior 24‐month primary patency compared to PTA (79.8% vs. 46.9%; log rank P |
| doi_str_mv | 10.1002/ccd.28048 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6594002</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2189942217</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5098-c750d3fa1a1a6f5a77aaf23b091240b830c62f5393985176020a78cb2957887d3</originalsourceid><addsrcrecordid>eNp1kkluFTEQhlsIREJgwQWQJVYsXmK7B7dZIEXvESBKxIIgsbPcbvvFUbfdeAg0K47AGTkBR6DeQAQLZMlD1a-vBldRPCX4mGBMT5Tqj2mLq_ZecUhqSheMNp_u7--EV81B8SjGG4wxbyh_WByUmFWsavlh8WsV8vrn9x_Ky6R71Mlh8N6hWx1ijii7vX3SQeUknfZgTUG6OOTROjkg6dbWT4OMaUbGB5SuNQi0TKN2CXmDJFiCj2qAPVmFBh2tdxFZt9XGDGxjlQWW0aMPWyZEDP6rHeExAd0mvTGHpMP8ElHId9YyoKBjHlLcRNmgLldX4KGElOjD2Sk6l5N0CHLt_Wi_QREpQJDHxQMjh6if7M-j4uPZ66vl28XF-zfvlqcXC1Vj3i4Uq3FfGklgNaaWjElpaNlhTmiFu7bEqqGmLnnJ25qwBlMsWas6ymvWtqwvj4pXO-6Uu1H3CroBpYkpQFFhFl5a8a_H2Wux9reiqXkFnwqA53tA8J-zjknc-Byg5VFQ0nJeUUoYqF7sVAp6HIM2dxEIFpvhEDAcYjscoH32d0p3yj_TAIKTneCLHfT8f5JYLlc75G_8Vc0M</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2189942217</pqid></control><display><type>article</type><title>Drug‐coated balloon versus uncoated percutaneous transluminal angioplasty for the treatment of atherosclerotic lesions in the superficial femoral and proximal popliteal artery: 2‐year results of the MDT‐2113 SFA Japan randomized trial</title><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><creator>Iida, Osamu ; Soga, Yoshimitsu ; Urasawa, Kazushi ; Saito, Shigeru ; Jaff, Michael R. ; Wang, Hong ; Ookubo, Hiroko ; Yokoi, Hiroyoshi</creator><creatorcontrib>Iida, Osamu ; Soga, Yoshimitsu ; Urasawa, Kazushi ; Saito, Shigeru ; Jaff, Michael R. ; Wang, Hong ; Ookubo, Hiroko ; Yokoi, Hiroyoshi ; MDT-2113 SFA Japan Investigators ; On behalf of the MDT‐2113 SFA Japan Investigators</creatorcontrib><description>Objectives
To assess the longer‐term safety and efficacy of the IN.PACT Admiral (MDT‐2113) drug‐coated balloon (DCB) for the treatment of de novo and non‐stented restenotic lesions in the superficial femoral and/or proximal popliteal arteries versus uncoated percutaneous transluminal angioplasty (PTA) in a Japanese cohort.
Background
Although DCBs are the newest endovascular strategy for patients with peripheral artery disease presenting with femoropopliteal lesions, there remains a paucity of results in non‐Caucasian populations.
Methods
IN.PACT SFA Japan is an independently‐adjudicated, prospective, multicenter, randomized, single‐blinded trial. Endpoints through 2 years included primary patency and a composite safety endpoint of freedom from device‐ and procedure‐related death through 30 days, freedom from target limb major amputation and freedom from clinically‐driven target vessel revascularization at 24 months.
Results
One hundred patients were assigned by 2:1 randomization to treatment with the IN.PACT Admiral DCB (n = 68) or PTA (n = 32). The groups were well‐matched at baseline. Mean lesion length for the DCB and PTA groups were 9.15 ± 5.85 and 8.89 ± 6.01 cm (P = 0.838), respectively. Patients treated with DCB exhibited superior 24‐month primary patency compared to PTA (79.8% vs. 46.9%; log rank P < 0.001). The 24‐month clinically driven target lesion revascularization rate was 9.1% for DCB versus 20.7% for PTA (P = 0.177). There were no device‐ or procedure‐related deaths, major amputations, or thromboses in either group.
Conclusions
Two‐year results from IN.PACT SFA Japan demonstrated persistently superior patency and low CD‐TLR rates through 2 years when compared to uncoated PTA in Japanese patients. These data are consistent with other IN.PACT DCB trials.</description><identifier>ISSN: 1522-1946</identifier><identifier>EISSN: 1522-726X</identifier><identifier>DOI: 10.1002/ccd.28048</identifier><identifier>PMID: 30747489</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Amputation ; Angioplasty ; Angioplasty, Balloon - adverse effects ; Angioplasty, Balloon - instrumentation ; Arteries ; Arteriosclerosis ; Atherosclerosis ; balloon angioplasty ; Cardiovascular Agents - administration & dosage ; Cardiovascular Agents - adverse effects ; Cardiovascular system ; Clinical trials ; Coated Materials, Biocompatible ; drug‐coated balloon ; Equipment Design ; Female ; Femoral Artery - diagnostic imaging ; Femoral Artery - physiopathology ; Femur ; Humans ; Japan ; Lesions ; Limb Salvage ; Male ; Middle Aged ; Patients ; Peripheral Arterial Disease - diagnostic imaging ; Peripheral Arterial Disease - physiopathology ; Peripheral Arterial Disease - therapy ; peripheral artery disease ; Peripheral Vascular Disease ; Popliteal Artery - diagnostic imaging ; Popliteal Artery - physiopathology ; Progression-Free Survival ; Prospective Studies ; Risk Factors ; Single-Blind Method ; Thromboembolism ; Time Factors ; Vascular Access Devices ; Vascular diseases ; Vascular Patency ; Young Adult</subject><ispartof>Catheterization and cardiovascular interventions, 2019-03, Vol.93 (4), p.664-672</ispartof><rights>2019 The Authors. published by Wiley Periodicals, Inc.</rights><rights>2019 The Authors. Catheterization and Cardiovascular Interventions published by Wiley Periodicals, Inc.</rights><rights>2019 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5098-c750d3fa1a1a6f5a77aaf23b091240b830c62f5393985176020a78cb2957887d3</citedby><cites>FETCH-LOGICAL-c5098-c750d3fa1a1a6f5a77aaf23b091240b830c62f5393985176020a78cb2957887d3</cites><orcidid>0000-0001-6829-7304 ; 0000-0001-9560-1228</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fccd.28048$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fccd.28048$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30747489$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Iida, Osamu</creatorcontrib><creatorcontrib>Soga, Yoshimitsu</creatorcontrib><creatorcontrib>Urasawa, Kazushi</creatorcontrib><creatorcontrib>Saito, Shigeru</creatorcontrib><creatorcontrib>Jaff, Michael R.</creatorcontrib><creatorcontrib>Wang, Hong</creatorcontrib><creatorcontrib>Ookubo, Hiroko</creatorcontrib><creatorcontrib>Yokoi, Hiroyoshi</creatorcontrib><creatorcontrib>MDT-2113 SFA Japan Investigators</creatorcontrib><creatorcontrib>On behalf of the MDT‐2113 SFA Japan Investigators</creatorcontrib><title>Drug‐coated balloon versus uncoated percutaneous transluminal angioplasty for the treatment of atherosclerotic lesions in the superficial femoral and proximal popliteal artery: 2‐year results of the MDT‐2113 SFA Japan randomized trial</title><title>Catheterization and cardiovascular interventions</title><addtitle>Catheter Cardiovasc Interv</addtitle><description>Objectives
To assess the longer‐term safety and efficacy of the IN.PACT Admiral (MDT‐2113) drug‐coated balloon (DCB) for the treatment of de novo and non‐stented restenotic lesions in the superficial femoral and/or proximal popliteal arteries versus uncoated percutaneous transluminal angioplasty (PTA) in a Japanese cohort.
Background
Although DCBs are the newest endovascular strategy for patients with peripheral artery disease presenting with femoropopliteal lesions, there remains a paucity of results in non‐Caucasian populations.
Methods
IN.PACT SFA Japan is an independently‐adjudicated, prospective, multicenter, randomized, single‐blinded trial. Endpoints through 2 years included primary patency and a composite safety endpoint of freedom from device‐ and procedure‐related death through 30 days, freedom from target limb major amputation and freedom from clinically‐driven target vessel revascularization at 24 months.
Results
One hundred patients were assigned by 2:1 randomization to treatment with the IN.PACT Admiral DCB (n = 68) or PTA (n = 32). The groups were well‐matched at baseline. Mean lesion length for the DCB and PTA groups were 9.15 ± 5.85 and 8.89 ± 6.01 cm (P = 0.838), respectively. Patients treated with DCB exhibited superior 24‐month primary patency compared to PTA (79.8% vs. 46.9%; log rank P < 0.001). The 24‐month clinically driven target lesion revascularization rate was 9.1% for DCB versus 20.7% for PTA (P = 0.177). There were no device‐ or procedure‐related deaths, major amputations, or thromboses in either group.
Conclusions
Two‐year results from IN.PACT SFA Japan demonstrated persistently superior patency and low CD‐TLR rates through 2 years when compared to uncoated PTA in Japanese patients. These data are consistent with other IN.PACT DCB trials.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Amputation</subject><subject>Angioplasty</subject><subject>Angioplasty, Balloon - adverse effects</subject><subject>Angioplasty, Balloon - instrumentation</subject><subject>Arteries</subject><subject>Arteriosclerosis</subject><subject>Atherosclerosis</subject><subject>balloon angioplasty</subject><subject>Cardiovascular Agents - administration & dosage</subject><subject>Cardiovascular Agents - adverse effects</subject><subject>Cardiovascular system</subject><subject>Clinical trials</subject><subject>Coated Materials, Biocompatible</subject><subject>drug‐coated balloon</subject><subject>Equipment Design</subject><subject>Female</subject><subject>Femoral Artery - diagnostic imaging</subject><subject>Femoral Artery - physiopathology</subject><subject>Femur</subject><subject>Humans</subject><subject>Japan</subject><subject>Lesions</subject><subject>Limb Salvage</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Patients</subject><subject>Peripheral Arterial Disease - diagnostic imaging</subject><subject>Peripheral Arterial Disease - physiopathology</subject><subject>Peripheral Arterial Disease - therapy</subject><subject>peripheral artery disease</subject><subject>Peripheral Vascular Disease</subject><subject>Popliteal Artery - diagnostic imaging</subject><subject>Popliteal Artery - physiopathology</subject><subject>Progression-Free Survival</subject><subject>Prospective Studies</subject><subject>Risk Factors</subject><subject>Single-Blind Method</subject><subject>Thromboembolism</subject><subject>Time Factors</subject><subject>Vascular Access Devices</subject><subject>Vascular diseases</subject><subject>Vascular Patency</subject><subject>Young Adult</subject><issn>1522-1946</issn><issn>1522-726X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNp1kkluFTEQhlsIREJgwQWQJVYsXmK7B7dZIEXvESBKxIIgsbPcbvvFUbfdeAg0K47AGTkBR6DeQAQLZMlD1a-vBldRPCX4mGBMT5Tqj2mLq_ZecUhqSheMNp_u7--EV81B8SjGG4wxbyh_WByUmFWsavlh8WsV8vrn9x_Ky6R71Mlh8N6hWx1ijii7vX3SQeUknfZgTUG6OOTROjkg6dbWT4OMaUbGB5SuNQi0TKN2CXmDJFiCj2qAPVmFBh2tdxFZt9XGDGxjlQWW0aMPWyZEDP6rHeExAd0mvTGHpMP8ElHId9YyoKBjHlLcRNmgLldX4KGElOjD2Sk6l5N0CHLt_Wi_QREpQJDHxQMjh6if7M-j4uPZ66vl28XF-zfvlqcXC1Vj3i4Uq3FfGklgNaaWjElpaNlhTmiFu7bEqqGmLnnJ25qwBlMsWas6ymvWtqwvj4pXO-6Uu1H3CroBpYkpQFFhFl5a8a_H2Wux9reiqXkFnwqA53tA8J-zjknc-Byg5VFQ0nJeUUoYqF7sVAp6HIM2dxEIFpvhEDAcYjscoH32d0p3yj_TAIKTneCLHfT8f5JYLlc75G_8Vc0M</recordid><startdate>20190301</startdate><enddate>20190301</enddate><creator>Iida, Osamu</creator><creator>Soga, Yoshimitsu</creator><creator>Urasawa, Kazushi</creator><creator>Saito, Shigeru</creator><creator>Jaff, Michael R.</creator><creator>Wang, Hong</creator><creator>Ookubo, Hiroko</creator><creator>Yokoi, Hiroyoshi</creator><general>John Wiley & Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6829-7304</orcidid><orcidid>https://orcid.org/0000-0001-9560-1228</orcidid></search><sort><creationdate>20190301</creationdate><title>Drug‐coated balloon versus uncoated percutaneous transluminal angioplasty for the treatment of atherosclerotic lesions in the superficial femoral and proximal popliteal artery: 2‐year results of the MDT‐2113 SFA Japan randomized trial</title><author>Iida, Osamu ; Soga, Yoshimitsu ; Urasawa, Kazushi ; Saito, Shigeru ; Jaff, Michael R. ; Wang, Hong ; Ookubo, Hiroko ; Yokoi, Hiroyoshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5098-c750d3fa1a1a6f5a77aaf23b091240b830c62f5393985176020a78cb2957887d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Amputation</topic><topic>Angioplasty</topic><topic>Angioplasty, Balloon - adverse effects</topic><topic>Angioplasty, Balloon - instrumentation</topic><topic>Arteries</topic><topic>Arteriosclerosis</topic><topic>Atherosclerosis</topic><topic>balloon angioplasty</topic><topic>Cardiovascular Agents - administration & dosage</topic><topic>Cardiovascular Agents - adverse effects</topic><topic>Cardiovascular system</topic><topic>Clinical trials</topic><topic>Coated Materials, Biocompatible</topic><topic>drug‐coated balloon</topic><topic>Equipment Design</topic><topic>Female</topic><topic>Femoral Artery - diagnostic imaging</topic><topic>Femoral Artery - physiopathology</topic><topic>Femur</topic><topic>Humans</topic><topic>Japan</topic><topic>Lesions</topic><topic>Limb Salvage</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Patients</topic><topic>Peripheral Arterial Disease - diagnostic imaging</topic><topic>Peripheral Arterial Disease - physiopathology</topic><topic>Peripheral Arterial Disease - therapy</topic><topic>peripheral artery disease</topic><topic>Peripheral Vascular Disease</topic><topic>Popliteal Artery - diagnostic imaging</topic><topic>Popliteal Artery - physiopathology</topic><topic>Progression-Free Survival</topic><topic>Prospective Studies</topic><topic>Risk Factors</topic><topic>Single-Blind Method</topic><topic>Thromboembolism</topic><topic>Time Factors</topic><topic>Vascular Access Devices</topic><topic>Vascular diseases</topic><topic>Vascular Patency</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Iida, Osamu</creatorcontrib><creatorcontrib>Soga, Yoshimitsu</creatorcontrib><creatorcontrib>Urasawa, Kazushi</creatorcontrib><creatorcontrib>Saito, Shigeru</creatorcontrib><creatorcontrib>Jaff, Michael R.</creatorcontrib><creatorcontrib>Wang, Hong</creatorcontrib><creatorcontrib>Ookubo, Hiroko</creatorcontrib><creatorcontrib>Yokoi, Hiroyoshi</creatorcontrib><creatorcontrib>MDT-2113 SFA Japan Investigators</creatorcontrib><creatorcontrib>On behalf of the MDT‐2113 SFA Japan Investigators</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Wiley Online Library Free Content</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Catheterization and cardiovascular interventions</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Iida, Osamu</au><au>Soga, Yoshimitsu</au><au>Urasawa, Kazushi</au><au>Saito, Shigeru</au><au>Jaff, Michael R.</au><au>Wang, Hong</au><au>Ookubo, Hiroko</au><au>Yokoi, Hiroyoshi</au><aucorp>MDT-2113 SFA Japan Investigators</aucorp><aucorp>On behalf of the MDT‐2113 SFA Japan Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Drug‐coated balloon versus uncoated percutaneous transluminal angioplasty for the treatment of atherosclerotic lesions in the superficial femoral and proximal popliteal artery: 2‐year results of the MDT‐2113 SFA Japan randomized trial</atitle><jtitle>Catheterization and cardiovascular interventions</jtitle><addtitle>Catheter Cardiovasc Interv</addtitle><date>2019-03-01</date><risdate>2019</risdate><volume>93</volume><issue>4</issue><spage>664</spage><epage>672</epage><pages>664-672</pages><issn>1522-1946</issn><eissn>1522-726X</eissn><abstract>Objectives
To assess the longer‐term safety and efficacy of the IN.PACT Admiral (MDT‐2113) drug‐coated balloon (DCB) for the treatment of de novo and non‐stented restenotic lesions in the superficial femoral and/or proximal popliteal arteries versus uncoated percutaneous transluminal angioplasty (PTA) in a Japanese cohort.
Background
Although DCBs are the newest endovascular strategy for patients with peripheral artery disease presenting with femoropopliteal lesions, there remains a paucity of results in non‐Caucasian populations.
Methods
IN.PACT SFA Japan is an independently‐adjudicated, prospective, multicenter, randomized, single‐blinded trial. Endpoints through 2 years included primary patency and a composite safety endpoint of freedom from device‐ and procedure‐related death through 30 days, freedom from target limb major amputation and freedom from clinically‐driven target vessel revascularization at 24 months.
Results
One hundred patients were assigned by 2:1 randomization to treatment with the IN.PACT Admiral DCB (n = 68) or PTA (n = 32). The groups were well‐matched at baseline. Mean lesion length for the DCB and PTA groups were 9.15 ± 5.85 and 8.89 ± 6.01 cm (P = 0.838), respectively. Patients treated with DCB exhibited superior 24‐month primary patency compared to PTA (79.8% vs. 46.9%; log rank P < 0.001). The 24‐month clinically driven target lesion revascularization rate was 9.1% for DCB versus 20.7% for PTA (P = 0.177). There were no device‐ or procedure‐related deaths, major amputations, or thromboses in either group.
Conclusions
Two‐year results from IN.PACT SFA Japan demonstrated persistently superior patency and low CD‐TLR rates through 2 years when compared to uncoated PTA in Japanese patients. These data are consistent with other IN.PACT DCB trials.</abstract><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>30747489</pmid><doi>10.1002/ccd.28048</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-6829-7304</orcidid><orcidid>https://orcid.org/0000-0001-9560-1228</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1522-1946 |
| ispartof | Catheterization and cardiovascular interventions, 2019-03, Vol.93 (4), p.664-672 |
| issn | 1522-1946 1522-726X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6594002 |
| source | Wiley Online Library - AutoHoldings Journals; MEDLINE |
| subjects | Adult Aged Aged, 80 and over Amputation Angioplasty Angioplasty, Balloon - adverse effects Angioplasty, Balloon - instrumentation Arteries Arteriosclerosis Atherosclerosis balloon angioplasty Cardiovascular Agents - administration & dosage Cardiovascular Agents - adverse effects Cardiovascular system Clinical trials Coated Materials, Biocompatible drug‐coated balloon Equipment Design Female Femoral Artery - diagnostic imaging Femoral Artery - physiopathology Femur Humans Japan Lesions Limb Salvage Male Middle Aged Patients Peripheral Arterial Disease - diagnostic imaging Peripheral Arterial Disease - physiopathology Peripheral Arterial Disease - therapy peripheral artery disease Peripheral Vascular Disease Popliteal Artery - diagnostic imaging Popliteal Artery - physiopathology Progression-Free Survival Prospective Studies Risk Factors Single-Blind Method Thromboembolism Time Factors Vascular Access Devices Vascular diseases Vascular Patency Young Adult |
| title | Drug‐coated balloon versus uncoated percutaneous transluminal angioplasty for the treatment of atherosclerotic lesions in the superficial femoral and proximal popliteal artery: 2‐year results of the MDT‐2113 SFA Japan randomized trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T06%3A46%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Drug%E2%80%90coated%20balloon%20versus%20uncoated%20percutaneous%20transluminal%20angioplasty%20for%20the%20treatment%20of%20atherosclerotic%20lesions%20in%20the%20superficial%20femoral%20and%20proximal%20popliteal%20artery:%202%E2%80%90year%20results%20of%20the%20MDT%E2%80%902113%20SFA%20Japan%20randomized%20trial&rft.jtitle=Catheterization%20and%20cardiovascular%20interventions&rft.au=Iida,%20Osamu&rft.aucorp=MDT-2113%20SFA%20Japan%20Investigators&rft.date=2019-03-01&rft.volume=93&rft.issue=4&rft.spage=664&rft.epage=672&rft.pages=664-672&rft.issn=1522-1946&rft.eissn=1522-726X&rft_id=info:doi/10.1002/ccd.28048&rft_dat=%3Cproquest_pubme%3E2189942217%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2189942217&rft_id=info:pmid/30747489&rfr_iscdi=true |